Company Filing History:
1 out of 16 
1 out of 150 
Years Active: 1995
Title: The Innovative Contributions of Ross W. Stephens
Introduction
Ross W. Stephens is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of biotechnology, particularly in the development of proteins that play a crucial role in cancer research and treatment. His work has implications for understanding tumor invasion and metastasis, which are critical areas in medical science.
Latest Patents
Ross W. Stephens holds a patent for Human PAI-2 - Minactivin, also known as Plasminogen Activator Inhibitor-2 (PAI-2). This protein inactivator of urokinase-type plasminogen activator has been shown to be a natural inactivator associated with invasive tumors. The patent indicates that PAI-2 is a crucial element in the body's normal defense against tumor invasion and metastasis. The production of minactivin can be achieved by cultivating minactivin-producing cells in vitro and recovering the cell culture supernatant. By controlling the culture conditions, minactivin can be produced in a partially purified form for use in the diagnosis and treatment of tumors. The specification also discloses methods for the production of PAI-2 through recombinant DNA technology, characterization of a PAI-2 gene sequence, and the expression and purification of large quantities of biologically active PAI-2 from a recombinant host.
Career Highlights
Throughout his career, Ross W. Stephens has worked with prominent organizations such as Biotechnology Australia Pty Ltd and The Australian National University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Jeffrey P. Golder and Toni Marie Antalis. Their collaborative efforts have further advanced the understanding of PAI-2 and its applications in cancer treatment.
Conclusion
Ross W. Stephens is a distinguished inventor whose work on Human PAI-2 - Minactivin has the potential to significantly impact cancer research and treatment. His contributions to biotechnology highlight the importance of innovation in addressing complex medical challenges.